PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration

PsiOxus Therapeutics Ltd has updated the agreement to advance its clinical collaboration with Bristol-Myers Squibb Co BMY to evaluate PsiOxus' tumor re-engineering platform, in combination with BMY's Opdivo (nivolumab) to treat a range of tumor types.
The first stage of this collaboration combined BMY's Opdivo with PsiOxus' enadenotucirev in Phase 1 SPICE study to evaluate the combination's safety and tolerability and optimize the combination intravenous dosing regimen.
The revised collaboration will build upon the initial study data and will combine Opdivo with PsiOxus' NG-641.
NG-641 is a tumor re-engineering product using PsiOxus' Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform based upon the enadenotucirev vector.
Under the terms of this agreement, PsiOxus will be responsible for conducting the Phase 1 study.
Patient recruitment is expected to start in the third quarter of this year.
Price Action: BMY shares are up 0.2% at $62.1 in the premarket trading on the last check Wednesday.

MomentumN/A

Growth65.55

QualityN/A

Value31.65

Short

Medium

Long